临床药物治疗杂志
臨床藥物治療雜誌
림상약물치료잡지
CLINICAL MEDICATION JOURNAL
2015年
1期
35-38
,共4页
李倩%魏红%张秀丽%贾鹏娟%杨桂彬
李倩%魏紅%張秀麗%賈鵬娟%楊桂彬
리천%위홍%장수려%가붕연%양계빈
幽门螺杆菌%四联疗法%雷贝拉唑
幽門螺桿菌%四聯療法%雷貝拉唑
유문라간균%사련요법%뢰패랍서
Helicobacter pylori%quadruple regimen%rabeprazole
目的：比较不同剂量雷贝拉唑为基础的含铋四联10 d疗法幽门螺杆菌Helicobacter pylori根除率和症状缓解率。方法：H. pylori阳性的胃炎或十二指肠溃疡患者随机接受包含不同剂量雷贝拉唑的四联疗法：雷贝拉唑10 mg（A组）或20 mg（B组）、克拉霉素500 mg、阿莫西林1000 mg和枸橼酸铋钾220 mg，bid，疗程10 d。停药4周后复查13C-呼气试验，并了解症状缓解情况。结果：共有121例患者纳入本试验，其中A组60例，B组61例。A组H. pylori根除率为83.3%（意向分析，ITT,符合方案分析，PP），B组H. pylori根除率为91.8%（ITT），94.9%（PP）；A组疼痛缓解率为81.3%（ITT, PP），B组疼痛缓解率为93.5%（ITT），95.6%（PP）。按PP群组分析B组H. pylori根除率及疼痛缓解率明显高于A组，按ITT组群分析，两组方案H. pylori根除率及疼痛缓解率无明显差异。结论：含大剂量雷贝拉唑的含铋四联10 d疗法较标准剂量雷贝拉唑四联疗法可以获得更高的H. pylori根除率及疼痛缓解率。
目的：比較不同劑量雷貝拉唑為基礎的含鉍四聯10 d療法幽門螺桿菌Helicobacter pylori根除率和癥狀緩解率。方法：H. pylori暘性的胃炎或十二指腸潰瘍患者隨機接受包含不同劑量雷貝拉唑的四聯療法：雷貝拉唑10 mg（A組）或20 mg（B組）、剋拉黴素500 mg、阿莫西林1000 mg和枸櫞痠鉍鉀220 mg，bid，療程10 d。停藥4週後複查13C-呼氣試驗，併瞭解癥狀緩解情況。結果：共有121例患者納入本試驗，其中A組60例，B組61例。A組H. pylori根除率為83.3%（意嚮分析，ITT,符閤方案分析，PP），B組H. pylori根除率為91.8%（ITT），94.9%（PP）；A組疼痛緩解率為81.3%（ITT, PP），B組疼痛緩解率為93.5%（ITT），95.6%（PP）。按PP群組分析B組H. pylori根除率及疼痛緩解率明顯高于A組，按ITT組群分析，兩組方案H. pylori根除率及疼痛緩解率無明顯差異。結論：含大劑量雷貝拉唑的含鉍四聯10 d療法較標準劑量雷貝拉唑四聯療法可以穫得更高的H. pylori根除率及疼痛緩解率。
목적：비교불동제량뢰패랍서위기출적함필사련10 d요법유문라간균Helicobacter pylori근제솔화증상완해솔。방법：H. pylori양성적위염혹십이지장궤양환자수궤접수포함불동제량뢰패랍서적사련요법：뢰패랍서10 mg（A조）혹20 mg（B조）、극랍매소500 mg、아막서림1000 mg화구연산필갑220 mg，bid，료정10 d。정약4주후복사13C-호기시험，병료해증상완해정황。결과：공유121례환자납입본시험，기중A조60례，B조61례。A조H. pylori근제솔위83.3%（의향분석，ITT,부합방안분석，PP），B조H. pylori근제솔위91.8%（ITT），94.9%（PP）；A조동통완해솔위81.3%（ITT, PP），B조동통완해솔위93.5%（ITT），95.6%（PP）。안PP군조분석B조H. pylori근제솔급동통완해솔명현고우A조，안ITT조군분석，량조방안H. pylori근제솔급동통완해솔무명현차이。결론：함대제량뢰패랍서적함필사련10 d요법교표준제량뢰패랍서사련요법가이획득경고적H. pylori근제솔급동통완해솔。
Objective:To compare the efifcacy and tolerability of a 10-day double-dose rabeprazole-based quadruple regimen composed of bismuth with a standard-dose rabeprazole quadruple regimen in eradicatingHelicobacter pylori infection and relieving symptoms.Methods:Patients withH. pylori-positive duodenal ulcer disease as well as gastritis were randomly assigned to receive rabeprazole-based quadruple regimens at different doses: bismuth potassium citrate 220 mg, clarithromycin 500 mg, amoxicillin 1 000 mg, plus either rabeprazole 10 mg (Group A) or 20 mg (Group B), all twice daily for 10 days.H. pylori status was determined by urease test, and13C-urea breath test. Eradication ofH. pyloriand symptomatic relief status were also determined. Results: A total of 121 patients were included into this clinical trial. Group A was composed of 60 patients and Group B was composed of 61 patients. Intention-to-treat eradication rates of Group A and Group B were 83.3% and 91.8% respectively, and per protocol eradication rates of Group A and Group B were 83.3% and 94.9% respectively. Intention-to-treat pain relieving rates of Group A and Group B were 81.3% and 93.5% respectively and per protocol pain relieving rates of Group A and Group B were 81.3% and 95.6% respectively. According to per protocol analysis,H. pylori eradication rate and pain relieving rate of Group B were signiifcantly higher than those of Group A, and based on Intention-to-treat analysis, there was no signiifcantly difference in HP eradication rate and pain relieving rate between both groups.Conclusion:The 10-day double-dose rabeprazole containing bismuth quadruple regimen achieved both better eradication rate and pain relieving rate than standard-dose rabeprazole quadruple regimens forH. pylori eradication.
